Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.34 |
| ▸ | PTGES | O14684 | 9/20 | 0.34 |
| ▸ | PLAT | P00750 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | SLC33A1 | O00400 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3745603 | 0.91 | PLAT (0.36) | AGTR1PLATSLC33A1 | |
| SCHEMBL3529020 | 0.89 | PTGES (0.37) | PTGESHDAC1HDAC6HDAC5 | |
| SCHEMBL3530754 | 0.89 | PTGES (0.38) | TRPM8AGTR1PTGES | |
| SCHEMBL3527487 | 0.87 | TRPM8 (0.39) | TRPM8PTGES | |
| SCHEMBL3529145 | 0.84 | DGAT1 (0.35) | TRPM8AGTR1PLATDGAT1 | |
| SCHEMBL3530945 | 0.83 | CASP3 (0.33) | TRPM8PTGES | |
| SCHEMBL3529210 | 0.83 | PTGES (0.36) | TRPM8AGTR1PTGESDGAT1 | |
| SCHEMBL15338120 | 0.81 | AGTR1 (0.34) | AGTR1HDAC1HDAC6HDAC5SLC33A1 | |
| SCHEMBL13343366 | 0.81 | AGTR1 (0.34) | AGTR1HDAC1HDAC6HDAC5SLC33A1 | |
| SCHEMBL3526025 | 0.81 | RET (0.35) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931337-B1 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-10-23 | — | — | EP | disclosed |
| EP-1931337-B1 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-7709481-B2 | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| US-7709481-B2 | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| US-7709481-B2 | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1931337-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039177-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039177-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | PPARD, PPARA, PPARG | TRPM8 3008/4885AGTR1 151/4885PTGES 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.